| pubmed-article:9007137 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9007137 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:9007137 | lifeskim:mentions | umls-concept:C1522449 | lld:lifeskim |
| pubmed-article:9007137 | lifeskim:mentions | umls-concept:C0007131 | lld:lifeskim |
| pubmed-article:9007137 | lifeskim:mentions | umls-concept:C0079083 | lld:lifeskim |
| pubmed-article:9007137 | lifeskim:mentions | umls-concept:C0144576 | lld:lifeskim |
| pubmed-article:9007137 | lifeskim:mentions | umls-concept:C1517927 | lld:lifeskim |
| pubmed-article:9007137 | lifeskim:mentions | umls-concept:C0205420 | lld:lifeskim |
| pubmed-article:9007137 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:9007137 | pubmed:issue | 6 Suppl 16 | lld:pubmed |
| pubmed-article:9007137 | pubmed:dateCreated | 1997-2-25 | lld:pubmed |
| pubmed-article:9007137 | pubmed:abstractText | Previously untreated patients with stages IIIA or IIIB non-small cell lung cancer entered this phase II study to evaluate the activity and toxicity of combined paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin and concurrent radiation. Patients received paclitaxel 50 mg/m2/wk as a 1-hour infusion and carboplatin area under the concentration-time curve of 2/wk for 7 weeks with radiation to the primary tumor and regional lymph nodes (44 Gy) followed by a boost to the tumor (22 Gy). In addition, patients received two additional cycles of paclitaxel 200 mg/m2 and carboplatin (area under the concentration-time curve of 6) 3 weeks apart. From March 1995 to February 1996, 23 patients entered the study and their overall response rate (complete plus partial responses) was 82%. The major toxicity was esophagitis. Nine patients (45%) had experienced grades 3 or 4 esophagitis by the end of the 7-week concurrent phase. Seven of the nine patients recovered from the esophagitis within 2 weeks and received the additional two cycles of paclitaxel 200 mg/m2 and carboplatin (area under the concentration-time curve of 6). Only one patient (4%) had grade 4 pneumonitis; this patient also recovered within 2 weeks and received the final two doses of combined chemotherapy. Therapy with paclitaxel, carboplatin, and concurrent radiation is a promising treatment for patients with locally advanced non-small cell lung cancer; it has a high response rate and acceptable toxicity. | lld:pubmed |
| pubmed-article:9007137 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9007137 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9007137 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9007137 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9007137 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9007137 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9007137 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9007137 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9007137 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:9007137 | pubmed:issn | 0093-7754 | lld:pubmed |
| pubmed-article:9007137 | pubmed:author | pubmed-author:GrazianiYY | lld:pubmed |
| pubmed-article:9007137 | pubmed:author | pubmed-author:ChungCC | lld:pubmed |
| pubmed-article:9007137 | pubmed:author | pubmed-author:ChouLL | lld:pubmed |
| pubmed-article:9007137 | pubmed:author | pubmed-author:SafranHH | lld:pubmed |
| pubmed-article:9007137 | pubmed:author | pubmed-author:AkerleyWW | lld:pubmed |
| pubmed-article:9007137 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9007137 | pubmed:volume | 23 | lld:pubmed |
| pubmed-article:9007137 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9007137 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9007137 | pubmed:pagination | 117-9 | lld:pubmed |
| pubmed-article:9007137 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9007137 | pubmed:meshHeading | pubmed-meshheading:9007137-... | lld:pubmed |
| pubmed-article:9007137 | pubmed:meshHeading | pubmed-meshheading:9007137-... | lld:pubmed |
| pubmed-article:9007137 | pubmed:meshHeading | pubmed-meshheading:9007137-... | lld:pubmed |
| pubmed-article:9007137 | pubmed:meshHeading | pubmed-meshheading:9007137-... | lld:pubmed |
| pubmed-article:9007137 | pubmed:meshHeading | pubmed-meshheading:9007137-... | lld:pubmed |
| pubmed-article:9007137 | pubmed:meshHeading | pubmed-meshheading:9007137-... | lld:pubmed |
| pubmed-article:9007137 | pubmed:meshHeading | pubmed-meshheading:9007137-... | lld:pubmed |
| pubmed-article:9007137 | pubmed:meshHeading | pubmed-meshheading:9007137-... | lld:pubmed |
| pubmed-article:9007137 | pubmed:meshHeading | pubmed-meshheading:9007137-... | lld:pubmed |
| pubmed-article:9007137 | pubmed:meshHeading | pubmed-meshheading:9007137-... | lld:pubmed |
| pubmed-article:9007137 | pubmed:meshHeading | pubmed-meshheading:9007137-... | lld:pubmed |
| pubmed-article:9007137 | pubmed:meshHeading | pubmed-meshheading:9007137-... | lld:pubmed |
| pubmed-article:9007137 | pubmed:meshHeading | pubmed-meshheading:9007137-... | lld:pubmed |
| pubmed-article:9007137 | pubmed:meshHeading | pubmed-meshheading:9007137-... | lld:pubmed |
| pubmed-article:9007137 | pubmed:meshHeading | pubmed-meshheading:9007137-... | lld:pubmed |
| pubmed-article:9007137 | pubmed:meshHeading | pubmed-meshheading:9007137-... | lld:pubmed |
| pubmed-article:9007137 | pubmed:meshHeading | pubmed-meshheading:9007137-... | lld:pubmed |
| pubmed-article:9007137 | pubmed:meshHeading | pubmed-meshheading:9007137-... | lld:pubmed |
| pubmed-article:9007137 | pubmed:meshHeading | pubmed-meshheading:9007137-... | lld:pubmed |
| pubmed-article:9007137 | pubmed:meshHeading | pubmed-meshheading:9007137-... | lld:pubmed |
| pubmed-article:9007137 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:9007137 | pubmed:articleTitle | Paclitaxel plus carboplatin and concurrent radiation therapy for patients with locally advanced non-small cell lung cancer. | lld:pubmed |
| pubmed-article:9007137 | pubmed:affiliation | Center for Radiation Oncology, Vanderbilt University Medical School, Nashville, TN 37232-5671, USA. | lld:pubmed |
| pubmed-article:9007137 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9007137 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9007137 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:9007137 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:9007137 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9007137 | lld:pubmed |
